DelveInsight’s “Anaphylaxis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Anaphylaxis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Anaphylaxis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Anaphylaxis: An Overview
Anaphylaxis is an acute, potentially life-threatening, generalized, or systemic allergic reaction that is mediated by the degranulation of mast cells and basophils. The condition usually develops suddenly and gets worse very quickly. The symptoms include feeling lightheaded or faint, breathing difficulties – such as fast, shallow breathing, wheezing, fast heartbeat, clammy skin, confusion, and anxiety, collapsing or losing consciousness. There may also be other allergy symptoms, including an itchy, raised rash (hives), feeling or being sick, swelling (angioedema), or stomach pain.
Anaphylaxis is the result of the immune system, overreacting to a trigger. Common anaphylaxis triggers include foods (like nuts, milk, fish, shellfish, eggs, and some fruits), medicines (some antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin), insect stings (particularly wasp and bee stings), general anesthetics, contrast agents (like dyes used in some medical tests to help certain areas of the body show up better on scans), latex and others. In some cases, there is no obvious trigger. This is known as idiopathic anaphylaxis.
Anaphylaxis Market Key Facts
-
Yu et al. (2018) conducted a study titled “The Epidemiology of Anaphylaxis”, wherein the lifetime prevalence of anaphylaxis was estimated at 0.05–2% in the USA and approximately 3% in Europe. The study also mentioned that in the UK, patients presenting to paramedics and first aides estimated 0.2% of emergency cases due to anaphylaxis.
-
According to a review by Shaker et al., (2020), the lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1%. Medications and stinging insects are the leading triggers in adults, with foods and stinging insects the most frequently implicated triggers in children and adolescents.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Anaphylaxis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Anaphylaxis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Anaphylaxis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Anaphylaxis Epidemiology, Segmented as –
-
Prevalent Population of Anaphylaxis in the 7MM (2019–32)
-
Diagnosed and Treatable Cases of Anaphylaxis in the 7MM (2019–32)
-
Trigger-specific Population of Anaphylaxis (Food, Medications, and others) in the 7MM (2019–32)
Anaphylaxis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Anaphylaxis market or expected to be launched during the study period. The analysis covers the Anaphylaxis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Anaphylaxis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Anaphylaxis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/anaphylaxis-market
Anaphylaxis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Anaphylaxis. Currently, Hikma Pharmaceuticals is leading the therapeutics market with its Anaphylaxis drug candidates in the most advanced stage of clinical development.
Leading Players in the Anaphylaxis Therapeutics Market Include
-
Aquestive Therapeutics
-
Stella Pharma
-
Nasus Pharma
-
Shenox Pharmaceuticals
-
Hikma Pharmaceuticals
-
MannKind
And Many Others
Anaphylaxis Companies in the Therapeutics Market Include
-
AQST-108: Aquestive Therapeutics
-
AQST-109: Aquestive Therapeutics
-
NS-002: Nasus Pharma
-
AbbieSense technology: Wyss Institute
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/anaphylaxis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Anaphylaxis Competitive Intelligence Analysis
4. Anaphylaxis Market Overview at a Glance
5. Anaphylaxis Disease Background and Overview
6. Anaphylaxis Patient Journey
7. Anaphylaxis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Anaphylaxis Treatment Algorithm, Current Treatment, and Medical Practices
9. Anaphylaxis Unmet Needs
10. Key Endpoints of Anaphylaxis Treatment
11. Anaphylaxis Marketed Products
12. Anaphylaxis Emerging Drugs and Latest Therapeutic Advances
13. Anaphylaxis Seven Major Market Analysis
14. Attribute Analysis
15. Anaphylaxis Market Outlook (In US, EU5, and Japan)
16. Anaphylaxis Access and Reimbursement Overview
17. KOL Views on the Anaphylaxis Market
18. Anaphylaxis Market Drivers
19. Anaphylaxis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/anaphylaxis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Cryptococcosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cryptococcosis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Cryptococcosis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/